Crescent Sterling Ltd. Has $3.39 Million Stock Position in Johnson & Johnson $JNJ

Crescent Sterling Ltd. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,214 shares of the company’s stock after selling 1,421 shares during the quarter. Johnson & Johnson makes up about 3.8% of Crescent Sterling Ltd.’s investment portfolio, making the stock its 5th largest position. Crescent Sterling Ltd.’s holdings in Johnson & Johnson were worth $3,393,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of JNJ. Brighton Jones LLC raised its position in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. bought a new position in Johnson & Johnson in the 1st quarter valued at $218,000. Clear Creek Financial Management LLC raised its position in Johnson & Johnson by 24.2% in the 1st quarter. Clear Creek Financial Management LLC now owns 9,493 shares of the company’s stock valued at $1,574,000 after purchasing an additional 1,852 shares during the last quarter. Lansing Street Advisors raised its position in Johnson & Johnson by 2.7% in the 1st quarter. Lansing Street Advisors now owns 5,820 shares of the company’s stock valued at $965,000 after purchasing an additional 154 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Johnson & Johnson by 4.9% in the 1st quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 536,067 shares of the company’s stock valued at $88,901,000 after buying an additional 25,183 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

JNJ opened at $189.02 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48. The firm has a market capitalization of $455.40 billion, a PE ratio of 18.25, a PEG ratio of 2.19 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The business’s 50-day simple moving average is $183.28 and its 200 day simple moving average is $167.56.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday. Wells Fargo & Company set a $212.00 target price on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Finally, Daiwa America raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.